Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway - eBioMedicine
CRZ in MET-Rearranged NSCLC - Lung Cancer - 2016 American Society of Clinical Oncology Annual Meeting - Oncology - Clinical Care Options
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer - Clinical Lung Cancer
Crizotinib in Patients With MET-Amplified NSCLC - Journal of Thoracic Oncology
ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer: Cell Reports
Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology
Crizotinib is an Orally Active, ATP-Competitive ALK and c-Met inhibitor - Network of Cancer Research
MET mutations identified following crizotinib treatment. (A–C) The... | Download Scientific Diagram
Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. - Abstract - Europe PMC
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
Downregulation of MET in H1993 cells, effects of crizotinib on EGFR... | Download Scientific Diagram
Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Crizotinib hydrochloride | c-Met 阻害剤
cに応じられた阻害 | c-Met Inhibition
Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors | Future Oncology
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
Crizotinib inhibits activation of MET pathway caused by MET extracellular SEMA domain duplication - Lung Cancer
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation - Clinical Lung Cancer
Crizotinib (PF-02341066) | ALK/c-Met/ROS1阻害剤 | MedChemExpress
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Effect of Crizotinib on c-MET expression in c-MET altered cancer cells.... | Download Scientific Diagram
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
PLOS ONE: Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
